Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02978625
Recruitment Status : Suspended (Other - Stage 1 data analysis)
First Posted : December 1, 2016
Last Update Posted : August 6, 2019
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Suspended
  Estimated Primary Completion Date : January 1, 2020
  Estimated Study Completion Date : January 1, 2020